Diamyd Medical AB (publ) Stock Nasdaq Stockholm
Equities
SE0005162880
Biotechnology & Medical Research
Sales 2024 * | 3M 276K | Sales 2025 * | 3M 276K | Capitalization | 931M 85.61M |
---|---|---|---|---|---|
Net income 2024 * | -133M -12.22M | Net income 2025 * | -165M -15.17M | EV / Sales 2024 * | 281 x |
Net cash position 2024 * | 87M 8M | Net cash position 2025 * | 128M 11.76M | EV / Sales 2025 * | 268 x |
P/E ratio 2024 * |
-7.01
x | P/E ratio 2025 * |
-5.64
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.58% |
Latest transcript on Diamyd Medical AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 16-04-09 |
Founder | 83 | 95-12-31 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 09-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 83 | 95-12-31 | |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 52 | 21-04-27 |
1st Jan change | Capi. | |
---|---|---|
-3.39% | 102B | |
+2.61% | 96.84B | |
-0.70% | 21.48B | |
-18.14% | 20.82B | |
-7.22% | 18.6B | |
-40.70% | 16.81B | |
-26.89% | 13.78B | |
+1.12% | 13.4B | |
+22.25% | 11.06B |